Affordable Access

deepdyve-link
Publisher Website

Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.

Authors
  • McLaughlin, Brian
  • Im, Annie
  • Raptis, Anastasios
  • Agha, Mounzer
  • Hou, Jing-Zhou
  • Redner, Robert
  • Duggal, Shrina
  • Lin, Yan
  • Smith, Clay
  • Boyiadzis, Michael
Type
Published Article
Journal
International Journal of Hematology
Publisher
Springer-Verlag
Publication Date
Dec 01, 2012
Volume
96
Issue
6
Pages
743–747
Identifiers
DOI: 10.1007/s12185-012-1192-9
PMID: 23132594
Source
Medline
License
Unknown

Abstract

The most effective regimen for relapsed acute myeloid leukemia (AML) patients who do not achieve complete remission (CR) after a course of salvage therapy has not been established. We evaluated the efficacy and toxicity of fludarabine and cytarabine in patients with AML in first relapse who did not respond to a course of salvage chemotherapy with mitoxantrone and etoposide. CR was achieved in 39 % of treated patients, and in 47 % of patients with a favorable/intermediate-risk karyotype. The median overall survival was 4.75 months. The median survival for patients achieving CR with fludarabine-cytarabine was significantly higher than for those who did not respond to therapy (9.6 vs. 4.5 months, P = 0.04). Our data suggest that the fludarabine-cytarabine regimen merits further investigation in relapsed AML patients with favorable or intermediate-risk karyotype with persistent leukemia after a course of salvage therapy.

Report this publication

Statistics

Seen <100 times